Ocugen

We're #hiring a new Principal Clinical Data Manager in Malvern, Pennsylvania. Apply today or share this post with your network.

We are proud to celebrate International Women’s Day on Saturday, March 8 and recognize the many talented and hardworking women at Ocugen who make achieving our goals possible. #IWD2025 #AccelerateAction #CourageousInnovation

Ocugen announced positive opinion of EMA’s Committee for advanced therapies for ATMP classification for novel modifier gene therapy candidate OCU410 for Geographic atrophy and OCU410ST for Stargardt disease. ATMP classification is granted to medicines that can offer groundbreaking opportunities for the treatment of disease and accelerates the regulatory review timeline of this potential one-time gene therapy for life. Read the full press release here: https://bit.ly/4brIzBF #GeographicAtrophy #Stargardt #GeneTherapy #BlindnessDiseases

Today, Ocugen reported fourth quarter and full year 2024 financial results along with a general business update. More details are in our press release: https://bit.ly/3QJHcow #GeneTherapy #Ophthalmology #BlindnessDiseases #RetinitisPigmentosa #GeographicAtrophy #Stargardt

Ocugen CMO, Dr. Huma Qamar, spoke with Medicine Maker about the work Ocugen is doing to address rare diseases, the challenges facing this area of medicine, and her optimal scenario for assisting rare disease patients. Read the full article here: https://bit.ly/4ipvPxE #RareDisease #IRD #RetinitisPigmentosa #Stargardt #GeneTherapy

We're #hiring a new Principal Clinical Data Manager in Malvern, Pennsylvania. Apply today or share this post with your network.

Ocugen celebrates Rare Disease Day and supports the need to raise awareness and generate change for the 300 million people worldwide living with a rare disease. The Company is committed to addressing the significant unmet medical needs that exist for patients living with inherited retinal disease though our modifier gene therapy platform. To learn more about how you can be a part of this important effort, visit: https://lnkd.in/gk6hbAF #RareDiseaseDay #IRD #RetinitisPigmentosa #StargardtDisease

We're #hiring a new Vice President, Manufacturing & Supply in Malvern, Pennsylvania. Apply today or share this post with your network.

Today, Ocugen announced that alignment has been reached with the FDA to move forward with a Phase 2/3 pivotal confirmatory clinical trial for OCU410ST which, if positive, can be the basis of a biologics license application (BLA) submission in 2027. Recent data from the OCU410ST GARDian clinical trial have shown significant improvements in both structural and functional outcomes. Additionally, OCU410ST has consistently demonstrated a very favorable safety and tolerability profile. Read the full press release here: https://bit.ly/41z8Yu3 #StargardtDisease #IRD #BlindnessDiseases #ClinicalTrials

On Wednesday, March 5, 2025, Ocugen will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2024 financial results and provide a business update. For more information on how to join, click here: https://bit.ly/3EMkXLX